Advantage Alpha Capital Partners’s Agilon Health AGL Stock Holding History

Advantage Alpha Capital Partners’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14,559	Closed	-$2.38M	–	168
2024 Q2	$2.38M	Sell	14,559 -585	-4%	-$83.3K	0.52%	71
2024 Q1	$2.31M	Sell	15,144 -1,352	-8%	-$225K	0.43%	87
2023 Q4	$5.18M	Buy	16,496 +1,301	+9%	+$471K	0.98%	43
2023 Q3	$6.75M	Buy	15,195 +6,779	+81%	+$3.06M	1.42%	25
2023 Q2	$3.65M	Buy	8,416 +2,600	+45%	+$1.46M	0.73%	65
2023 Q1	$3.45M	Buy	5,816 +1,757	+43%	+$984K	0.72%	65
2022 Q4	$1.64M	Buy	+4,059	New	+$1.9M	0.33%	82
2022 Q3	–	Sell	-13,065	Closed	-$7.13M	–	91
2022 Q2	$7.13M	Buy	13,065 +1,242	+11%	+$628K	1.23%	43
2022 Q1	$7.49M	Buy	+11,823	New	+$6.09M	1.12%	37

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advantage Alpha Capital Partners's AGL Position: Q3 2024 in Review

Advantage Alpha Capital Partners sold out of Agilon Health (AGL) in Q3 2024, closing a stake of 14,559 shares — an estimated $2.38M sold.

Advantage Alpha Capital Partners first reported a position in AGL in Q1 2022 and held it in 9 quarters. The position peaked at $7.49M in Q1 2022. 209 funds tracked by Wall St. Rank hold AGL as of Q3 2024.

Advantage Alpha Capital Partners reported no remaining Agilon Health position as of Q3 2024 after selling out during the quarter.
Advantage Alpha Capital Partners sold 14,559 Agilon Health shares in Q3 2024, an estimated $2.38M.
Advantage Alpha Capital Partners first reported a position in Agilon Health in Q1 2022 and held it in 9 quarters.
Advantage Alpha Capital Partners's Agilon Health position peaked at $7.49M in Q1 2022.
209 funds tracked by Wall St. Rank held Agilon Health as of Q3 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2024, filed 13 Nov 2024.